RecruitingNCT06445322

Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)

Prescreening Study to Identify Potential Participants With ABCA4-related Retinopathy for ACDN-01 Clinical Trials

Sponsor

Ascidian Therapeutics, Inc

Enrollment

50 participants

Start Date

Jun 20, 2024

Study Type

OBSERVATIONAL

Conditions

Stargardt Disease Stargardt Disease 1

Summary

This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials.

Eligibility

Min Age: 5 Years

Inclusion Criteria2

Presence of mutations in the ABCA4 gene
ABCA4 retinopathy phenotype (Stargardt disease type 1 or cone-rod dystrophy)

Exclusion Criteria3

The presence of pathogenic or likely pathogenic mutations in other genes known to cause cone-rod dystrophy or Stargardt maculopathy
Retinal disease other than ABCA4-related retinopathy
Presence of a medical condition (systemic or ophthalmic), psychiatric condition, including substance abuse disorder, or physical examination or laboratory finding that may in the opinion of the principal investigator and sponsor preclude adherence to the scheduled study visits, safe participation in the study, or affect the results of the study.

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.